Lantheus Buys Progenics To Combine Radiopharmaceuticals With Precision Diagnostics
Lantheus says the all-stock drug-diagnostics deal brings together complementary portfolios of ultrasound and radiopharmaceutical diagnostics with oncology therapeutics.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.